TABLE 3.

Primary and secondary outcomes of the lung ultrasound-guided treatment group and the usual care group.

Outcomes	Num. of event in LUS group	Num. of event in usual care group	RR/SMD/WMD (95% CI)	P	I 2
Primary outcome
MACE	111/588	187/578	0.59 (0.48 to 0.71)β	< 0.001	40.9
Secondary outcomes
All-cause mortality	28/414	26/404	1.06 (0.64 to 1.75)β	0.825	0
HF related rehospitalization	75/588	118/578	0.63 (0.40 to 0.99)β	0.046	54.7
Rate of less B-line number	141/190	128/189	1.09 (0.96 to 1.24)β	0.169	0
Hypokalemia	8/124	11/125	0.73 (0.30 to 1.76)β	0.487	40.0
Acute kidney injury	8/118	11/125	0.78 (0.12 to 5.15)β	0.793	71.7
Changes of B-lines	932	920	−3.86 (−8.09 to 0.38)§	0.169	97.3
Quality of life	932	920	1.55 (−0.14 to 3.24)ζ	0.073	98.4
Diuretic dosage	932	920	−0.88 (−0.21 to 1.97)ζ	0.113	98.1
Duration of hospitalization	932	920	−1.56 (−3.36 to 0.24)§	0.090	99.0
NT-proBNP level	932	920	−2.28 (−4.34 to −0.22)ζ	0.030	99.0

β, RR, relative risk; ζ, SMD, standardized mean difference; §, WMD, weighted mean difference.

MACE, major adverse cardiac event; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LUS, lung ultrasound.